118 173

Cited 3 times in

Rare Incidence of ROS1 Rearrangement in Cholangiocarcinoma

 Sun Min Lim  ;  Jeong Eun Yoo  ;  Kiat Hon Lim  ;  David Wai Meng Tai  ;  Byoung Chul Cho  ;  Young Nyun Park 
 CANCER RESEARCH AND TREATMENT, Vol.49(1) : 185-192, 2017 
Journal Title
Issue Date
Adult ; Aged ; Aged, 80 and over ; Bile Duct Neoplasms/diagnosis ; Bile Duct Neoplasms/genetics* ; Bile Duct Neoplasms/metabolism ; Bile Duct Neoplasms/surgery ; Cholangiocarcinoma/diagnosis ; Cholangiocarcinoma/genetics* ; Cholangiocarcinoma/metabolism ; Cholangiocarcinoma/surgery ; Female ; Gene Rearrangement* ; Genetic Association Studies ; Humans ; Immunohistochemistry ; In Situ Hybridization, Fluorescence ; Incidence ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Neoplasm Grading ; Neoplasm Metastasis ; Neoplasm Staging ; Prognosis ; Protein-Tyrosine Kinases/genetics* ; Protein-Tyrosine Kinases/metabolism ; Proto-Oncogene Proteins/genetics* ; Proto-Oncogene Proteins/metabolism ; Tumor Burden
Cholangiocarcinoma ; Fluorescent in situ hybridization ; ROS1
PURPOSE: The recent discovery and characterization of an oncogenic ROS1 gene rearrangement has raised significant interest because small molecule inhibitors are effective in these tumors. The aim of this study was to determine frequency and clinicopathological features associated with ROS1 rearrangement in patients with cholangiocarcinoma (CCA). MATERIALS AND METHODS: A total of 261 patients who underwent surgery for CCA between October 1997 and August 2013 were identified from an international, multi-institutional database. ROS1 rearrangement was evaluated by break-apart fluorescence in situ hybridization using tissue microarrays of these patients. RESULTS: Of 261 CCA evaluated, three cases (1.1%) showed ROS1 rearrangement by fluorescence in situ hybridization (FISH), all of which were derived from intrahepatic origin. ROS1 protein expression was observed in 38 samples (19.1%). Significantly larger tumor size was observed in ROS1 immunohistochemistry (IHC)-negative patients compared with ROS1 IHC-positive patients. ROS1 FISH-positive patients had a single tumor with a median size of 4 cm and well-to-moderate differentiation. Overall, there was no difference in terms of baseline characteristics, overall survival, and recurrence-free survival between ROS1-positive and -negative patients. CONCLUSION: ROS1 rearrangement was detected in 1.1% of CCA patients. Although rare, conduct of clinical trials using ROS1 inhibitors in these genetically unique patients is warranted.
Files in This Item:
T201700266.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > BioMedical Science Institute (의생명과학부) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Park, Young Nyun(박영년) ORCID logo https://orcid.org/0000-0003-0357-7967
Yoo, Jeong Eun(유정은)
Lim, Sun Min(임선민)
Cho, Byoung Chul(조병철) ORCID logo https://orcid.org/0000-0002-5562-270X
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.